Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Liver Neoplasms 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × ropidoxuridine × 1 year × Clear all
NCT02993146 2026-04-30

Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

National Cancer Institute (NCI)

Phase 1 Active not recruiting
11 enrolled 12 charts
CNSOther hematologic neoplasm

Brain Neoplasms, Hematologic Neoplasms

NCT02381561 2026-04-13

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
19 enrolled
Gastrointestinal

Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡